Britain approves Eli Lilly weight loss drugs

Britain has become the first European country to approve the use of the drug "Orforgibron" produced by Eli Lilly, aimed at weight loss and managing type 2 diabetes. The medication is based on the GLP-1 class of drugs and is taken once daily, following a thorough review of its safety and effectiveness. This development comes as part of pharmaceutical companies' efforts to develop non-injectable alternatives for obesity treatment, with the United States having approved it earlier in April under the name "FounDiao." Several companies, including Novo Nordisk and AstraZeneca, are now competing by testing oral medications for obesity.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل